Provided are certain benzothiazole, imidazothiazole, imidazopyrimidine and imidazopyridine compounds, including, for example:<structures> and pharmaceutically and physiologically acceptable salts, hydrates, and solvates thereof. Such compounds can be used as diagnostic ligands or labels of tau protein and PHF.
|Publication status||Published - 1 Apr 2010|
FingerprintDive into the research topics of 'Ligands for aggregated tau molecules: WO2010034982'. Together they form a unique fingerprint.
Development of treatments & diagnostics for Alzheimer’s disease
John Storey (Coordinator)
Impact: Other Impacts
Discovery and commercialisation of an entirely new drug for the treatment of Alzheimer's disease
Claude Wischik (Participant), Charles Harrington (Participant), John Storey (Participant), Janet Rickard (Participant), David Horsley (Participant), Thomas Baddeley (Participant), Steven Kemp (Participant), James Sinclair (Participant), Claudia Zabke (Participant), F. Theuring (Participant), F Stamer (Participant) & C Marshall (Participant)
Impact: Quality of life Impacts, Economic Impacts